<DOC>
	<DOCNO>NCT02346058</DOCNO>
	<brief_summary>Evaluation efficacy safety Esarin Gel subject chronic venous insufficiency varicose vein combine superficial vein thrombophlebitis .</brief_summary>
	<brief_title>Efficacy Safety Esarin Gel Chronic Venous Insufficiency Varicose Veins</brief_title>
	<detailed_description>Open-label , non-controlled study design three visit ( pre-treatment/baseline , treatment day 14 day 28 ) . Administered Esarin Gel twice daily 28 day subject chronic venous insufficiency rat CEAP 0 3 varicose vein combine superficial vein thrombophlebitis , comparison pre-treatment .</detailed_description>
	<mesh_term>Venous Insufficiency</mesh_term>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Thrombophlebitis</mesh_term>
	<criteria>1 . Patients sex , age 20 year old . The patient confirm his/her willingness participate study , inform aspect study might relevant his/her decision participate , sign date informed consent form , approve Institutional Review Board/ Ethics Committee ( IRB/EC ) . Presence chronic venous insufficiency rat functional class CEAP 0 3 . ( CEAP Classes : C0 : visible palpable sign venous disease , C1 : telangiectasies reticular vein . C2 : apparent Varicose vein , C3 : Edema ) Diagnosed superficial vein thrombophlebitis skin reaction redness , swell , fever pain symptom . 2 . Known allergy product 's ingredient pregnant breastfeed patient join clinical trail Patient sign inform consent form Deep vein thrombosis Cellulitis Stasis dermatitis The patient take nonsteroid antiinflammatory drug ( include oral , topical cream patch form )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>